Albany Molecular Research (AMRI) Reports Q4 Loss of $0.19; Guides Contract Revs
AMRI Hot Sheet
EPS Growth %: +200.0%Financial Fact:
Loss from operations: -1.95M
Today's EPS Names:
TARO, BRLI, TLB, More
Albany Molecular Research (NASDAQ: AMRI) reported Q4 EPS of ($0.19), versus ($0.16) reported last year. Revenue for the quarter came in at $46.6 million, versus $48.6 million reported last year.
Sees Q1 2012 contract revenue of $37-$40 million.
Sees FY2012 contract revenue of $176-$186 million.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Sees Q1 2012 contract revenue of $37-$40 million.
Sees FY2012 contract revenue of $176-$186 million.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Toro Co. (TTC) Tops Q1 EPS by 13c; Guides FY12 EPS Above Views; to Split Stock
- ATA, Inc. (ATAI) Misses Q4 EPS by 1c; Guides FY13 Revs Below
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
